Literature DB >> 10761648

In vivo assessment of the window of barrier opening after osmotic blood-brain barrier disruption in humans.

T Siegal1, R Rubinstein, F Bokstein, A Schwartz, A Lossos, E Shalom, R Chisin, J M Gomori.   

Abstract

OBJECT: Osmotic blood-brain barrier (BBB) disruption induced by intraarterial infusion of mannitol is used in conjunction with chemotherapy to treat human brain tumors. The time course to barrier closure, or the so-called therapeutic window, has been examined in animals but little information is available in humans. The authors, therefore assessed the time course to barrier closure after osmotic BBB disruption in humans.
METHODS: Disruption of the BBB was demonstrated using 99mTc-glucoheptonate (TcGH) single-photon emission computerized tomography (SPECT) scanning in 12 patients who were treated monthly with combination chemotherapy in conjunction with BBB disruption. The primary diagnosis was primary central nervous system lymphoma in seven patients and primitive neuroectodermal tumors in five. The TcGH (20 mCi) was injected at 1- to 480-minute intervals after osmotic BBB disruption, and patients underwent SPECT scanning after 4 hours. A total of 38 studies was performed. Good-to-excellent BBB disruption was obtained in 29 procedures and poor-to-moderate disruption was seen in the other nine studies. The TcGH indices correlated with the degree of BBB disruption as measured postprocedure on contrast-enhanced CT scans (r = 0.852). Mean baseline TcGH indices were 1.02+/-0.07. For the group of patients with good-to-excellent disruptions the mean indices at 1 minute postdisruption measured 2.19+/-0.18. After 40 minutes no significant change was noted (mean index 2.13+/-0.2). Then the indices declined more steeply and at 120 minutes after the disruption the index was 1.36+/-0.02. A very slow decline was noted between 120 and 240 minutes after mannitol infusion. At 240 minutes the barrier was still open for all good-to-excellent disruptions (index 1.33+/-0.08) but at 480 minutes the mean indices had returned to the baseline level.
CONCLUSIONS: Results of these in vivo human studies indicate that the time course to closure of the disrupted BBB for low-molecular-weight complexes is longer than previously estimated. The barrier is widely open during the first 40 minutes after osmotic BBB disruption and returns to baseline levels only after 6 to 8 hours following the induction of good or excellent disruption. These findings have important clinical implications for the design of therapeutic protocols.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10761648     DOI: 10.3171/jns.2000.92.4.0599

Source DB:  PubMed          Journal:  J Neurosurg        ISSN: 0022-3085            Impact factor:   5.115


  47 in total

1.  Convergence of normal stem cell and cancer stem cell developmental stage: Implication for differential therapies.

Authors:  Shengwen Calvin Li; Katherine L Lee; Jane Luo; Jiang F Zhong; William G Loudon
Journal:  World J Stem Cells       Date:  2011-09-26       Impact factor: 5.326

2.  Immediate CT findings following embolization of cerebral aneurysms: suggestion of blood-brain barrier or vascular permeability change.

Authors:  Seung Kug Baik; Yong Sun Kim; Hui Jung Lee; Jaechan Park; Gab Chul Kim
Journal:  Neuroradiology       Date:  2007-11-23       Impact factor: 2.804

Review 3.  Targeting the brain: rationalizing the novel methods of drug delivery to the central nervous system.

Authors:  Shailendra Joshi; Eugene Ornstein; Jeffrey N Bruce
Journal:  Neurocrit Care       Date:  2007       Impact factor: 3.210

4.  Impact of drug size on brain tumor and brain parenchyma delivery after a blood-brain barrier disruption.

Authors:  Marie Blanchette; Luc Tremblay; Martin Lepage; David Fortin
Journal:  J Cereb Blood Flow Metab       Date:  2014-02-12       Impact factor: 6.200

5.  Intra-arterial chemotherapy with osmotic blood-brain barrier disruption for aggressive oligodendroglial tumors: results of a phase I study.

Authors:  Daniel J Guillaume; Nancy D Doolittle; Seymur Gahramanov; Nancy A Hedrick; Johnny B Delashaw; Edward A Neuwelt
Journal:  Neurosurgery       Date:  2010-01       Impact factor: 4.654

6.  Targeting ischemic penumbra Part II: selective drug delivery using liposome technologies.

Authors:  Shimin Liu; Steven R Levine; H Richard Winn
Journal:  J Exp Stroke Transl Med       Date:  2011

7.  Alkylglycerol opening of the blood-brain barrier to small and large fluorescence markers in normal and C6 glioma-bearing rats and isolated rat brain capillaries.

Authors:  Bernhard Erdlenbruch; Mehrnaz Alipour; Gert Fricker; David S Miller; Wilfried Kugler; Hansjörg Eibl; Max Lakomek
Journal:  Br J Pharmacol       Date:  2003-11-03       Impact factor: 8.739

8.  Acute effects of short-chain alkylglycerols on blood-brain barrier properties of cultured brain endothelial cells.

Authors:  P Hülper; S Veszelka; F R Walter; H Wolburg; P Fallier-Becker; J Piontek; I E Blasig; M Lakomek; W Kugler; M A Deli
Journal:  Br J Pharmacol       Date:  2013-08       Impact factor: 8.739

Review 9.  The effect of thermal therapy on the blood-brain barrier and blood-tumor barrier.

Authors:  Bhuvic Patel; Peter H Yang; Albert H Kim
Journal:  Int J Hyperthermia       Date:  2020-07       Impact factor: 3.914

10.  Brain endothelial cell-cell junctions: how to "open" the blood brain barrier.

Authors:  Svetlana M Stamatovic; Richard F Keep; Anuska V Andjelkovic
Journal:  Curr Neuropharmacol       Date:  2008-09       Impact factor: 7.363

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.